Ibogaine Safety & Cardiac Risk
The single most important thing to understand before considering ibogaine: it is physiologically demanding, and the heart is the main concern.
Ibogaine’s promise is inseparable from its risk. It can prolong the heart’s QT interval and has been associated with serious arrhythmias; fatalities have been documented, overwhelmingly in unsupervised settings without proper screening. This is why every credible protocol treats ibogaine as a cardiac case first and a psychedelic experience second.
Why the heart comes first
Ibogaine can block a cardiac ion channel and lengthen the QT interval, which in vulnerable people can trigger dangerous rhythms. The danger rises with higher doses, dehydration, electrolyte imbalance, and — critically — co-administration of other QT-prolonging drugs. That is why an EKG and lab work are not optional formalities but the gatekeepers of the whole process.
What proper screening looks like
Responsible programs require a baseline EKG, bloodwork (including electrolytes and liver function), a cardiac and psychiatric history, and a full medication review. Clinical overviews such as this medical detox overview of ibogaine stress that certain conditions and medications are outright contraindications, and that dosing should never proceed on an unscreened patient.
Continuous monitoring, start to finish
Because the acute phase and its cardiac effects unfold over many hours, reputable protocols keep patients under continuous observation for 24–48 hours — ideally with telemetry, on-site oxygen, defibrillation readiness, staff trained in advanced cardiac life support, and a rapid hospital-transfer plan. The overview of how ibogaine is administered describes how test doses and staggered dosing fit into that monitored window.
Who should not take ibogaine
People with underlying heart disease, QT abnormalities, electrolyte disturbances, or who take QT-prolonging medications are at markedly higher risk, and many programs exclude them. Polysubstance use, certain psychiatric conditions, pregnancy, and adolescence are also commonly treated as exclusions or as requiring specialist evaluation. Honesty during screening is a safety measure, not a hurdle.
Safety FAQ
Is ibogaine dangerous?
It carries real, documented risk — chiefly cardiac. Risk is greatly reduced by proper screening and continuous monitoring, but never eliminated.
Who should not take ibogaine?
People with heart conditions, QT abnormalities, electrolyte problems, or who take QT-prolonging medications, among others. Screening exists to catch these.
What makes ibogaine safer?
EKG and lab screening, exclusion of high-risk patients, conservative dosing, and 24-48 hours of continuous medical monitoring with emergency readiness.